Press Releases
Date picker
Category
Results per page
Kancera provides new information on the ROR project in connection with the “U.S. Cancer Immunotherapy Partnering Mission”
In connection with presentations for pharmaceutical companies and universities during the "U.S. Cancer Immunotherapy Partnering Mission" (CIPM), 15 -19 September 2014, Kancera communicates new information regarding the company's ROR1-directed small…
Interim Report for Kancera AB (publ) Q2 2014
Regulatory
January 1 - June 30, 2014 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in…
Interim Report for Kancera AB (publ) Q1 2014
Regulatory
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there…
Kancera AB files patent for HDAC6 inhibitors against cancer
Kancera reports that the company has registered a patent application (EP14167988.6) for new compounds against cancer that selectively inhibit the enzyme HDAC6. The new patent application is based on the…
Update on the result of the collaboration between Kancera and Thomas Helleday
In 2013, a collaboration was initiated between Kancera and Professor Thomas Helleday at the Science for Life Laboratory, Karolinska Institutet , in order to advance unique research on metabolism of…
Full Year Report for Kancera AB (publ) 2013 January 1 – December 31, 2013
Regulatory
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there…
Kancera initiates the development of a vaccine against ROR to prevent relapse of cancer
Kancera reports that the company is initiating the development of a vaccine directed against ROR. This initiative is motivated by the residual disease in the form of a small number…
Kancera announces the discovery of a new class of compounds against cancer
Kancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe…
Interim Report for Kancera AB (publ) Q3 2013
Regulatory
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there…
Interim Report for Kancera AB (publ) Q2 2013
Regulatory
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there…